Host Defense Proteins and Peptides with Lipopolysaccharide-Binding Activity from Marine Invertebrates and Their Therapeutic Potential in Gram-Negative Sepsis

Mar Drugs. 2023 Nov 7;21(11):581. doi: 10.3390/md21110581.

Abstract

Sepsis is a life-threatening complication of an infectious process that results from the excessive and uncontrolled activation of the host's pro-inflammatory immune response to a pathogen. Lipopolysaccharide (LPS), also known as endotoxin, which is a major component of Gram-negative bacteria's outer membrane, plays a key role in the development of Gram-negative sepsis and septic shock in humans. To date, no specific and effective drug against sepsis has been developed. This review summarizes data on LPS-binding proteins from marine invertebrates (ILBPs) that inhibit LPS toxic effects and are of interest as potential drugs for sepsis treatment. The structure, physicochemical properties, antimicrobial, and LPS-binding/neutralizing activity of these proteins and their synthetic analogs are considered in detail. Problems that arise during clinical trials of potential anti-endotoxic drugs are discussed.

Keywords: Gram-negative sepsis; LPS-binding proteins/peptides; endotoxic shock; host defense proteins/peptids; innate immune system; lipopolysaccharide (LPS, endotoxin); marine invertebrates.

Publication types

  • Review

MeSH terms

  • Animals
  • Endotoxins
  • Gram-Negative Bacterial Infections* / drug therapy
  • Humans
  • Invertebrates / metabolism
  • Lipopolysaccharides / pharmacology
  • Peptides / pharmacology
  • Sepsis* / drug therapy

Substances

  • Lipopolysaccharides
  • Peptides
  • Endotoxins

Grants and funding

This research received no external funding.